Roche News | finanzen.ch

Roche Aktie VALOR 1203211 / ISIN CH0012032113

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

24.09.21	Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders (GlobeNewswire)
22.09.21	Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients (GlobeNewswire)
20.09.21	New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer (GlobeNewswire)
17.09.21	Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (GlobeNewswire)
15.09.21	Roche opens access to pathology imaging tools to improve patient care (GlobeNewswire)
09.09.21	Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases (GlobeNewswire)
07.09.21	Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers (GlobeNewswire)
27.08.21	Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
18.08.21	Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy (GlobeNewswire)
09.08.21	[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form (GlobeNewswire)
03.08.21	US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer (GlobeNewswire)
29.07.21	FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) (GlobeNewswire)
29.07.21	Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
22.07.21	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results (GlobeNewswire)
22.07.21	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit guten Halbjahresergebnissen (GlobeNewswire)
21.07.21	FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (GlobeNewswire)
20.07.21	Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 (GlobeNewswire)
19.07.21	New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A (GlobeNewswire)
09.07.21	WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis (GlobeNewswire)
02.07.21	Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care (GlobeNewswire)
28.06.21	Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
25.06.21	Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children (GlobeNewswire)
24.06.21	FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) (GlobeNewswire)
15.06.21	Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio (GlobeNewswire)
11.06.21	Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia (GlobeNewswire)
11.06.21	New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) (GlobeNewswire)
08.06.21	Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home (GlobeNewswire)
04.06.21	Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma (GlobeNewswire)
25.05.21	European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy (GlobeNewswire)
20.05.21	Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning (GlobeNewswire)
11.05.21	Roche to present data from one of the most comprehensive oncology portfolios at the 2021 ASCO Annual Meeting showcasing advancements for people living with cancer (GlobeNewswire)
05.05.21	Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer (GlobeNewswire)
28.04.21	US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for previously untreated metastatic bladder cancer (GlobeNewswire)
28.04.21	Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people (GlobeNewswire)
28.04.21	US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
23.04.21	CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
23.04.21	Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy (GlobeNewswire)
22.04.21	Roche purchases shares in tender offer for GenMark Diagnostics, Inc. (GlobeNewswire)
21.04.21	Roche mit soliden Ergebnissen im ersten Quartal 2021 (GlobeNewswire)
21.04.21	Roche reports solid results in the first quarter of 2021 (GlobeNewswire)
16.04.21	New data for Roche’s OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis (GlobeNewswire)
15.04.21	Roche’s Evrysdi continues to improve motor function and survival in babies with Type 1 Spinal Muscular Atrophy (SMA) (GlobeNewswire)
13.04.21	FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications (GlobeNewswire)
12.04.21	Phase III prevention trial showed subcutaneous administration of investigational antibody cocktail casirivimab and imdevimab reduced risk of symptomatic COVID-19 infections by 81% (GlobeNewswire)
08.04.21	New Roche data at 2021 AAN highlight impact and breadth of expanding neuroscience portfolio (GlobeNewswire)
07.04.21	Roche launches Elecsys Anti-p53 immunoassay to aid diagnosis of various cancer types (GlobeNewswire)
31.03.21	Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging (GlobeNewswire)
30.03.21	Roche’s Evrysdi approved by European Commission as first and only at home treatment for spinal muscular atrophy (GlobeNewswire)
26.03.21	Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer (GlobeNewswire)
25.03.21	Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	3’833.00	0.87 %	K V
Nestle	90.24	0.78 %	K V
Roche Hldg G	296.70	0.78 %	K V
Sonova Hldg	262.80	0.42 %	K V
Kuehne+Nagel Int	206.70	0.39 %	K V
Part Grp Hldg	1’291.50	-1.45 %	K V
Logitech Intl	77.34	-1.65 %	K V
Geberit	558.20	-1.86 %	K V
ABB	46.96	-2.69 %	K V
Swisscom	513.00	-3.93 %	K V

mehr

28.03.25		Angespannte Stimmung in New York: Dow Jones fällt letztendlich
28.03.25		Angespannte Stimmung in New York: Dow Jones gibt nachmittags nach
28.03.25		Freitagshandel in New York: S&P 500 gibt nachmittags nach
28.03.25		Novartis-Aktie: FDA erteilt erweiterte Zulassung für Krebsmedikament
28.03.25		Zurückhaltung in New York: Dow Jones präsentiert sich am Mittag schwächer